HealthEquity’s Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns.
Latest Ratings for HQY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Deutsche Bank | Maintains | Buy | |
| Dec 2021 | JP Morgan | Maintains | Overweight | |
| Dec 2021 | Deutsche Bank | Maintains | Buy |
